Language and verbal fluency outcome after bilateral subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
12 2022
Historique:
received: 24 06 2022
revised: 18 10 2022
accepted: 23 10 2022
pubmed: 4 11 2022
medline: 7 12 2022
entrez: 3 11 2022
Statut: ppublish

Résumé

Language disorders in Parkinson's Disease (PD) following bilateral subthalamic Nucleus Deep Brain Stimulation (STN-DBS) are common. To assess STN-DBS impact on language and observe clinical and anatomical predictors of poor outcome. We prospectively included PD patients undergoing STN-DBS. We performed a neuropsychological evaluation focusing on language before (V0), 3 days after (V1), and 3 months after (V2) surgery. Patients performed all assessments in ON drug condition, V1 with the stimulation turned OFF to evaluate the lesion effect, and V2 with the stimulation turned ON to evaluate the stimulation effect. Electrodes and active contact locations were determined with MRI-Atlas fusion. The stimulation parameters and the total electrical energy delivered (TEED) were recorded for each patient. 18 PD patients consecutively operated were included. We identified a decline in phonemic verbal fluency (VFP) at V1 and V2 (p = 0.023 and 0.032 respectively), as well as in semantic verbal fluency (VFS) (p = 0.025 and 0.019, respectively). There was a significant slowdown in the verbs naming test (p = 0.048). No other language alteration was recorded. There was no correlation between demographic or clinical factors and verbal fluency (VF) evolution. Active contact location within substantia nigra was associated with VFP worsening (p = 0.047), while elevated TEED on the left-sided electrode was associated with VFS decline (p = 0.021). VF was significantly altered following STN-DBS. Location outside the dorsolateral sensorimotor STN, and high stimulation power appeared to promote this decline. Other language domains remained stable.

Sections du résumé

BACKGROUND
Language disorders in Parkinson's Disease (PD) following bilateral subthalamic Nucleus Deep Brain Stimulation (STN-DBS) are common.
OBJECTIVE
To assess STN-DBS impact on language and observe clinical and anatomical predictors of poor outcome.
METHODS
We prospectively included PD patients undergoing STN-DBS. We performed a neuropsychological evaluation focusing on language before (V0), 3 days after (V1), and 3 months after (V2) surgery. Patients performed all assessments in ON drug condition, V1 with the stimulation turned OFF to evaluate the lesion effect, and V2 with the stimulation turned ON to evaluate the stimulation effect. Electrodes and active contact locations were determined with MRI-Atlas fusion. The stimulation parameters and the total electrical energy delivered (TEED) were recorded for each patient.
RESULTS
18 PD patients consecutively operated were included. We identified a decline in phonemic verbal fluency (VFP) at V1 and V2 (p = 0.023 and 0.032 respectively), as well as in semantic verbal fluency (VFS) (p = 0.025 and 0.019, respectively). There was a significant slowdown in the verbs naming test (p = 0.048). No other language alteration was recorded. There was no correlation between demographic or clinical factors and verbal fluency (VF) evolution. Active contact location within substantia nigra was associated with VFP worsening (p = 0.047), while elevated TEED on the left-sided electrode was associated with VFS decline (p = 0.021).
CONCLUSION
VF was significantly altered following STN-DBS. Location outside the dorsolateral sensorimotor STN, and high stimulation power appeared to promote this decline. Other language domains remained stable.

Identifiants

pubmed: 36327600
pii: S1353-8020(22)00351-0
doi: 10.1016/j.parkreldis.2022.10.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-18

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Guillemette Clément (G)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Thomas Wirth (T)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.

Lucile Haumesser (L)

Pôle de Santé Publique, Groupe Méthode en Recherche Clinique, CHU de Strasbourg, France.

Marie des Neiges Santin (MDN)

Service de Neurochirurgie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Jimmy Voirin (J)

Service de Neurochirurgie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Ouhaid Lagha-Boukbiza (O)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Céline Labonne (C)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Christine Tranchant (C)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.

Nadine Longato (N)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France.

Clélie Phillipps (C)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France.

Mathieu Anheim (M)

Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France. Electronic address: mathieu.anheim@chru-strasbourg.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH